2Medeiros EA.Treatment of adults with community-acquired respiratory tract infections: results of a multicentric clinical trial with gatifloxacin[J].Braz J Infect Dis, 2002, 6(4): 149-156.
3Anzueto A, Gotfried M, Wikler MA, et al.Efficacy and tolerability of gatifloxacin in community treatment of acute exacerbations of chronic bronchitis[J].Clin Ther, 2002, 24(6): 906-917.
4Carbon C.Comparison of side effects of levofloxacin versus other fluoroquinolones[J].Chemotherapy, 2001, 47(3): 9-14.
5Jaillon P, Morganroth J, Brumpt I, et al.Overview of electrocardiographic and cardiovascular safety data for sparfloxacin[J].J Antimicrob Chemother, 1996, 37(Suppl A): 161-167.
6Lipsky BA.Baker CA.Fluoroquinolone toxicity profiles: a review focusing on newer agents[J].Clin Infect Dis, 1999, 28(2): 352-364.
7Nakashima M, Uematsu T, Kosuge K, et al.Single-and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxyquinolone, in humans[J].Antimicrob Agents Chemother, 1995, 39 (12): 2635.
8Perry CM, Balfour JAB, Lamb HM.Gatifloxacin[J].Drugs, 1999, 58 (4): 683.
9Franca SA, Carvalho CR.Effectiveness, safety and tolerability of gatifloxacin, a new 8-methoxyfluoroquinolone, in the treatment of outpatients with community-acquired pneumonia: a Brazilian study[J].Braz J Infect Dis, 2002, 6(4): 157-163.
10Hosaka M, Yasue T, Fukuda H, et al.In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxyquinolone[J].Antimicrob Agents Chemother, 1992, 36(10): 2108.
